The incidence of chronic thromboembolic pulmonary hypertension (CTEPH) after an episode of acute pulmonary embolism (PE) is likely underestimated, a study suggests. This occurs despite the high frequency of symptoms consistent with CTEPH, underscoring that an appropriate diagnostic work-up of CTEPH is rarely undertaken. The study, “CTEPH: a…

Approximately 5,000 Americans are diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH) each year. The condition is a result of persistent obstruction of pulmonary blood vessels due to unresolved blood clots from previous episodes of acute pulmonary embolism. If patients do not receive treatment for CTEPH, they may develop…

In this video from the Fondazione Internazionale Menarini, Dr. Vittorio Pengo discusses his presentation of the pathophysiology and treatment of chronic thromboembolic pulmonary hypertension (CTEPH). MORE: Find out how doctors diagnosed pulmonary hypertension and CTEPH. Dr. Pengo explains that CTEPH is a treatable disease that occurs in 0.5…

Are you #phaware? March is Blood Clot Awareness Month. CTEPH is the only type of PH that is potentially curable. 1 in 25 people who have had a pulmonary embolism (PE) could develop CTEPH. A VQ scan is a critical tool in the diagnosis of CTEPH. Engage for a cure.

Balloon pulmonary angioplasty, a procedure to widen narrowed lung blood vessels, was still benefitting patients with chronic thromboembolic pulmonary hypertension (CTEPH) six months after doctors performed it, a Japanese study found. The procedure increased patients’ cardiac output, or amount of the blood the heart is pumping, and exercise capacity, researchers said.

Results from a retrospective study based on a claims database of U.S. patients with pulmonary embolism indicated that physicians are failing to recognize and diagnose thousands of cases of a serious lung disease, chronic thromboembolic pulmonary hypertension (CTEPH). The study, “Monitoring for Pulmonary Hypertension Following Pulmonary Embolism: The INFORM…

Researchers have developed a computer tomography pulmonary embolism residua index (CTPER-index) that may prove to be a useful tool for diagnosis and treatment decisions regarding chronic thromboembolic pulmonary hypertension and dyspnea. The research paper, “Computed tomography pulmonary embolism residua index (CTPER-index): a simple tool for pulmonary embolism residua description,” was…

Researchers at University of California, San Diego (UCSD) recently published findings in the journal Pulmonary Circulation revealing the prevalence of specific collateral arteries in patients with chronic thromboembolic pulmonary hypertension (CTEPH). The study is entitled “Prevalence of coronary artery-pulmonary artery collaterals in patients with chronic…

Bayer Healthcare recently announced the approval of its novel drug Adempas (riociguat), which has been listed by the Régie de l’assurance malady du Québec (RAMQ), the Québec public formulary, as the one and only treatment option for patients with chronic thromboembolic pulmonary hypertension (CTEPH). Québec is the first province to provide Adempas…

According to a recent study published in the journal Heart, RV afterload increases in patients with chronic thromboembolic pulmonary hypertension (CTEPH) during exercise, resulting in a marked reduction in RVEF and SV reserve. However, sildenafil may reverse this effect. In patients with…

When people talk about pulmonary hypertension (PH), they’re talking about a condition where high blood pressure in the lungs leads to the narrowing of the blood vessels to the heart, causing the right side of the heart to work much harder to pump oxygenated blood back into the lungs. This can then lead…

https://www.youtube.com/watch?v=WQnQxSoPkC8 In this video from Experts On CTEPH, Dr. Raymond L. Benza, MD, of Allegheny General Hospital, Pittsburgh, talks about the differential diagnosis of CTEPH. He defines the diseases, explains the symptoms and details how the diagnosis should be made. Learn more about…